• She had no role in the new studies, which were discussed Sunday at an American Society of Clinical Oncology conference in Chicago.

    NPR: Avastin Fails Studies In New Brain Tumor Patients

  • One is a new ultra-targeted drug for lung cancer that was one of the most intriguing drugs at the American Society for Clinical Oncology conference last June.

    FORBES: Pfizer's Big Pipeline Hope

  • Details of the research were announced at the European Conference on Clinical Aspects and Treatment of HIV-Infection in Athens.

    BBC: HIV drug combats resistance

  • The criteria put forth at the conference are research criteria, not for clinical practice yet.

    CNN: Children of Alzheimer's sufferers want to know their risk

  • The research was discussed Tuesday in a telephone news conference sponsored by the American Society of Clinical Oncology and two other cancer groups.

    WSJ: Study questions kidney cancer treatment in elderly

  • Novartis is emerging as the surprise winner at this year's annual meeting of the American Society of Clinical Oncology, the year's biggest cancer conference.

    FORBES: Magazine Article

  • However, at a hastily convened press conference, leading experts involved in conducting clinical trials for the drug argued that the cancer result was probably a fluke.

    FORBES: Another Blow For Merck And Schering

  • Physicians and scientists traded information on major clinical trials this week at an American Heart Association conference, sharing discoveries and treatment tactics for heart attack and stroke.

    CNN: Research closing in on heart disease

  • The 29-year-old firm has dominated this year's biggest cancer treatment conference, the annual meeting of the American Society of Clinical Oncology (ASCO), with its drugs Herceptin, Avastin and Tarceva.

    FORBES: Magazine Article

  • The drug findings were unveiled on Wednesday in a news conference ahead of the annual meeting of the American Society of Clinical Oncology, which begins May 31 in Chicago.

    WSJ: New Cancer Drugs Harness Power of Immune System

  • Abraxane, a cancer chemotherapy made by Celgene, slowed tumor growth and cut the risk of death in patients with advanced pancreatic cancer, according to results that will be presented at a conference on gastrointestinal tumors being held by the American Society of Clinical Oncology.

    FORBES: Celgene's Abraxane Extends Life By 1.8 Months In Advanced Pancreatic Cancer

  • However, at a Medtronic analyst meeting at the conference, lead trial investigator Gust Bardy from the Seattle Institute for Clinical Research insisted that such an approach would not be medically valid.

    FORBES: Cost Of Saving A Life Gets Higher

  • Better yet, Chief Executive Peter Dolan spoke on the conference call, after remaining almost silent as Bristol was savaged by clinical failures, plummeting sales and three years' worth of earnings restatements.

    FORBES: Magazine Article

  • On a conference call, James Shannon, the drug giant's head of clinical research, said the FDA wants more data studying Galvus in patients with impaired kidneys.

    FORBES: Magazine Article

  • But the results, which were released via a press conference and will be presented at the annual meeting of the American Society of Clinical Oncology in two weeks, were striking.

    FORBES: Pharmaceuticals

  • The day before the opening today of the ASH conference in Atlanta, TG Therapeitics announced it has initiated a phase 1 and 2 clinical trials to evaluate the safety, tolerability and efficacy of its product, TG-1101, a novel third-generation anti-CD20 monoclonal antibody, in combination with Revilimid for patients with relapsed or refractory B-cell lymphoid malignancies who were previously treated with anti-CD20 antibody therapy.

    FORBES: Don't Be Surprised If Underpriced Small-Cap Biotechs Catch Investors' Eye Once Again

  • The list, which includes five bacteria and one fungus, is described in the current issue of Clinical Infectious Diseases, a medical journal, and will also be unveiled as part of a press conference today.

    FORBES: The Most Dangerous Bacteria

  • On its recent Q4 conference call with analysts Pfizer confirmed the likely progression of its own Herceptin biosimilar program into Phase III clinical trials later this year.

    FORBES: Gamekeeper or Poacher? - Big Pharma's Stance on Biosimilars

$firstVoiceSent
- 来自原声例句
小调查
请问您想要如何调整此模块?

感谢您的反馈,我们会尽快进行适当修改!
进来说说原因吧 确定
小调查
请问您想要如何调整此模块?

感谢您的反馈,我们会尽快进行适当修改!
进来说说原因吧 确定